Safer chemicals using less animals: kick-off of the European ONTOX project.

Journal: Toxicology
Published Date:

Abstract

The 3Rs concept, calling for replacement, reduction and refinement of animal experimentation, is receiving increasing attention around the world, and has found its way to legislation, in particular in the European Union. This is aligned by continuing high-level efforts of the European Commission to support development and implementation of 3Rs methods. In this respect, the European project called "ONTOX: ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessment" was recently initiated with the goal to provide a functional and sustainable solution for advancing human risk assessment of chemicals without the use of animals in line with the principles of 21 century toxicity testing and next generation risk assessment. ONTOX will deliver a generic strategy to create new approach methodologies (NAMs) in order to predict systemic repeated dose toxicity effects that, upon combination with tailored exposure assessment, will enable human risk assessment. For proof-of-concept purposes, focus is put on NAMs addressing adversities in the liver, kidneys and developing brain induced by a variety of chemicals. The NAMs each consist of a computational system based on artificial intelligence and are fed by biological, toxicological, chemical and kinetic data. Data are consecutively integrated in physiological maps, quantitative adverse outcome pathway networks and ontology frameworks. Supported by artificial intelligence, data gaps are identified and are filled by targeted in vitro and in silico testing. ONTOX is anticipated to have a deep and long-lasting impact at many levels, in particular by consolidating Europe's world-leading position regarding the development, exploitation, regulation and application of animal-free methods for human risk assessment of chemicals.

Authors

  • Mathieu Vinken
    Department of In Vitro Toxicology and Dermato-Cosmetology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.
  • Emilio Benfenati
    Laboratory of Environmental Chemistry and Toxicology, Department of Environmental Health Sciences, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Via Giuseppe La Masa 19, 20156 Milan, Italy.
  • François Busquet
    Altertox, Brussels, Belgium.
  • José Castell
    Department of Biochemistry and Molecular Biology, University of Valencia-Spain, and Experimental Hepatology Unit, IIS Hospital La Fe of Valencia, CIBERehd, Spain.
  • Djork-Arné Clevert
    Department of Bioinformatics , Bayer AG , Berlin , Germany . Email: robin.winter@bayer.com.
  • Theo M de Kok
    Department of Toxicogenomics, GROW School for Oncology and Developmental Biology, Maastricht University, the Netherlands.
  • Hubert Dirven
    Norwegian Institute of Public Health Oslo Norway.
  • Ellen Fritsche
    IUF-Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany, and Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
  • Liesbet Geris
    Virtual Physiological Human Institute, Leuven, Belgium.
  • Rafael Gozalbes
    ProtoQSAR SL, Centro Europeo de Empresas Innovadoras (CEEI), Parque Tecnológico de Valencia, Valencia, Spain.
  • Thomas Hartung
    Center for Alternatives to Animal Testing (CAAT), Health and Whiting School of Engineering, Johns Hopkins University, Baltimore, MD, United States.
  • Danyel Jennen
    Department of Toxicogenomics, GROW School for Oncology and Developmental Biology, Maastricht University, the Netherlands.
  • Ramiro Jover
    Department of Biochemistry and Molecular Biology, University of Valencia-Spain, and Experimental Hepatology Unit, IIS Hospital La Fe of Valencia, CIBERehd, Spain.
  • Helena Kandarova
    Centre of Experimental Medicine SAS, Slovak Academy of Sciences, Bratislava, Slovakia.
  • Nynke Kramer
    Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands.
  • Cyrille Krul
    Innovative Testing in Life Sciences and Chemistry, Hogeschool Utrecht University of Applied Sciences Utrecht, the Netherlands.
  • Thomas Luechtefeld
    Johns Hopkins University, Bloomberg School of Public Health, Center for Alternatives to Animal Testing, Baltimore, MD, USA.
  • Rosalinde Masereeuw
    Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
  • Erwin Roggen
    3Rs Management and Consulting ApS, Lyngby, Denmark.
  • Stephan Schaller
    esqLABS GmbH, Saterland, Germany.
  • Tamara Vanhaecke
    Research Group of In VitroToxicology and Dermato-Cosmetology, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Brussels, Belgium.
  • Chihae Yang
    Molecular Networks GmbH, Nürnberg, Germany.
  • Aldert H Piersma
    Center for Health Protection, National Institute for Public Health and The Environment (RIVM), P.O. Box 1, 3720BA Bilthoven, The Netherlands; Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands.